Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives Final Approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 mg and 600 mg.25-01-2024
25-01-2024
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under Reg 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.23-01-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus and Synthon enter into an exclusive licensing and supply agreement for Palbociclib Tablets (generic version of IBRANCE) for the US market19-01-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives Final Approvals from the USFDA for Pimavanserin Capsules, 34 mg and Pimavanserin Tablets, 10 mg.17-01-2024
Zydus Lifesciences Ltd - 532321 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on December 31, 2023.08-01-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of newspaper publication06-01-2024
Zydus Lifesciences Ltd - 532321 - Announcement Under Regulation 30 Of SEBI LODR, 2015
Demand notice from Stamp Authority, Maharashtra04-01-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Credit Rating
Credit Rating03-01-2024
Zydus Lifesciences Ltd - 532321 - Disclosure Under Reg 30 Of The SEBI (LODR) Reg, 2015
Disclosure under Reg 30 of the SEBI (LODR) Reg, 201503-01-2024
Zydus Lifesciences Ltd - 532321 - Disclosure Under Reg 30 Of The SEBI (LODR) Reg, 2015
Disclosure under Reg 30 of the SEBI (LODR) Reg, 201503-01-2024